Treatment Development of Triheptanoin (C7) for Glucose Transporter Type I Deficiency (G1D): A Phase I Maximum Tolerable Dose Trial

Trial Profile

Treatment Development of Triheptanoin (C7) for Glucose Transporter Type I Deficiency (G1D): A Phase I Maximum Tolerable Dose Trial

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 May 2017

At a glance

  • Drugs Triheptanoin (Primary)
  • Indications De Vivo disease
  • Focus Adverse reactions
  • Most Recent Events

    • 18 May 2017 Planned End Date changed from 8 Mar 2025 to 29 Mar 2025.
    • 18 May 2017 Planned primary completion date changed from 8 Mar 2022 to 29 Mar 2022.
    • 28 Feb 2017 Planned End Date changed from 6 Feb 2025 to 8 Mar 2025.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top